- Home
- ADIL vs GLMD Comparison
ADIL vs GLMD Comparison
Compare ADIL & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADIL
- GLMD
- Stock Information
- Founded
- ADIL 2010
- GLMD 2000
- Country
- ADIL United States
- GLMD Israel
- Employees
- ADIL N/A
- GLMD N/A
- Industry
- ADIL Biotechnology: Pharmaceutical Preparations
- GLMD Biotechnology: Pharmaceutical Preparations
- Sector
- ADIL Health Care
- GLMD Health Care
- Exchange
- ADIL Nasdaq
- GLMD Nasdaq
- Market Cap
- ADIL 4.8M
- GLMD 4.5M
- IPO Year
- ADIL 2018
- GLMD 2014
- Fundamental
- Price
- ADIL $0.79
- GLMD $2.70
- Analyst Decision
- ADIL Strong Buy
- GLMD
- Analyst Count
- ADIL 1
- GLMD 0
- Target Price
- ADIL $8.00
- GLMD N/A
- AVG Volume (30 Days)
- ADIL 172.8K
- GLMD 21.6K
- Earning Date
- ADIL 03-31-2025
- GLMD 04-03-2025
- Dividend Yield
- ADIL N/A
- GLMD N/A
- EPS Growth
- ADIL N/A
- GLMD N/A
- EPS
- ADIL N/A
- GLMD N/A
- Revenue
- ADIL N/A
- GLMD N/A
- Revenue This Year
- ADIL N/A
- GLMD N/A
- Revenue Next Year
- ADIL N/A
- GLMD N/A
- P/E Ratio
- ADIL N/A
- GLMD N/A
- Revenue Growth
- ADIL N/A
- GLMD N/A
- 52 Week Low
- ADIL $0.72
- GLMD $2.24
- 52 Week High
- ADIL $4.17
- GLMD $23.80
- Technical
- Relative Strength Index (RSI)
- ADIL 40.52
- GLMD 49.41
- Support Level
- ADIL $0.76
- GLMD $2.24
- Resistance Level
- ADIL $0.85
- GLMD $2.72
- Average True Range (ATR)
- ADIL 0.05
- GLMD 0.20
- MACD
- ADIL 0.01
- GLMD 0.02
- Stochastic Oscillator
- ADIL 50.77
- GLMD 71.47
About ADIL Adial Pharmaceuticals Inc
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.